A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

被引：0
作者：
Rebecca L. Haffajee
Barbara Andraka-Christou
Jeremy Attermann
Anna Cupito
Jessica Buche
Angela J. Beck
机构：
[1] University of Michigan,From the Behavioral Health Workforce Research Center
[2] RAND Corporation,Department of Health Management and Policy
[3] University of Michigan School of Public Health,Injury Prevention Center, Department of Emergency Medicine
[4] University of Michigan Medical School,Department of Health Management & Informatics
[5] University of Central Florida,Department of Internal Medicine (Secondary Joint Appointment)
[6] University of Central Florida,Department of Health Behavior and Health Education
[7] the National Council for Behavioral Health,undefined
[8] University of Michigan School of Public Health,undefined
来源：
Substance Abuse Treatment, Prevention, and Policy | / 15卷
关键词：
Buprenorphine; Methadone; Naltrexone; Barriers; Physicians; Survey; Comparison; Referral; Dual diagnosis; Pregnant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 150 条
[1]  
Saloner B(2015)Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004–2013 JAMA 314 1515-SS42
[2]  
Karthikeyan S(2018)Policy pathways to address provider workforce barriers to buprenorphine treatment Am J Prev Med 54 S230-6
[3]  
Haffajee RL(2018)Moving addiction care to the mainstream — improving the quality of buprenorphine treatment N Engl J Med 379 4-145
[4]  
Bohnert ASB(2020)Comparative effectiveness of different treatment pathways for opioid use disorder JAMA Netw Open 3 137-922
[5]  
Lagisetty PA(2018)Medication for opioid use disorder after nonfatal opioid overdose and association with mortality Ann Intern Med 169 917-e63
[6]  
Saloner B(2013)Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009 Am J Public Health 103 e55-5
[7]  
Stoller KB(2015)National and state treatment need and capacity for opioid agonist medication-assisted treatment Am J Public Health 105 e196373-S207
[8]  
Alexander GC(2019)Characteristics of U.S. Counties with High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder JAMA Netw Open 2 35-26
[9]  
Wakeman SE(2017)Update on Barriers to Pharmacotherapy for Opioid Use Disorders Curr Psychiatry Rep 19 1-981
[10]  
Larochelle MR(2018)Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update J Rural Health 0 S199-225
12345678910